


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.




TIBC = total iron binding capacity
 MCV = mean corpuscular volume

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

PRESENTATION

TREATMENT



ESA = erythropoietin stimulating agents

¹ ESAs may be considered for patients who refuse blood transfusions after discussing the risks

² See FDA approved indications and CMS guidelines

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

SUGGESTED READINGS

Cable, C. A., Razavi, S. A., Roback, J. D., & Murphy, D. J. (2019). RBC Transfusion Strategies in the ICU: A Concise Review. *Critical Care Medicine*.

doi:10.1097/CCM.0000000000003985

Centers for Medicare and Medicaid Services. (2019). *Medicare National Coverage Determinations Manual*. Retrieved from: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/ncd103c1_Part2.pdf

Hébert, P. C., Wells, G., Blajchman, M. A., Marshall, J., Martin, C., Pagliarello, G., ... Transfusion Requirements in Critical Care Investigators for Canadian Critical Care Trials Groups. (1999). A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. *New England Journal of Medicine*, 340(6), 409-417. doi:10.1056/NEJM1999 02113400601

Mueller, M. M., Van Remoortel, H., Meybohm, P., Aranko, K., Aubron, C., Burger, R., ... Fergusson, D. (2019). Patient blood management: Recommendations from the 2018 Frankfurt Consensus Conference. *Jama*, 321(10), 983-997. doi:10.1001/jama.2019.0554

National Comprehensive Cancer Network. (2019). *Hematopoietic Growth Factors* (NCCN Guideline Version 2.2019). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf.

Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., ... Rarick, M. U. (2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. *Journal of Clinical Oncology*, 26(1), 132-149. doi: 10.1200/JCO.2007.14.3396

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

DEVELOPMENT CREDITS

This practice consensus statement is based on majority opinion of the Anemia experts at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

John Araujo, MD (Genitourinary Medical Oncology)
Gautam Borthakur, MD (Leukemia)
Alessandra Ferrajoli, MD (Leukemia)
Olga N. Fleckenstein♦
Sandra Horowitz, PharmD (Pharmacy Clinical Programs)
Michael Kroll, MD (Benign Hematology)
Laura Michaud, PharmD (Pharmacy Quality & Regulatory)
Christine Mowatt-Larsen, PharmD (Pharmacy Clinical Programs)
Milena Zhang, PharmD♦

♦ Clinical Effectiveness Development Team